LORAZEPAM

category:
124
LORAZEPAM
CALCUTIONS AREA
CLICK ON CALCULATOR

Infant Data

Results

MEDICAL INFORMATIONS

INDICATIONS

Anticonvulsant, acute management of patients with seizures refractory to conventional therapy.

CONTRAINDICATIONS

  • Premature infants as product contains benzyl alcohol.
  • Patients with known sensitivity to benzodiazepines, polyethylene glycol, propylene glycol, and benzyl alcohol; acute narrow-angle glaucoma.
  • Sleep apnea
  • Severe respiratory insufficiency unless mechanically ventilated.
  • Intra-arterial administration
  • Not recommended for use in patients with hepatic and/or renal failure

PRECAUTIONS

  • Neurologic:
    • Brain development in children may be affected by repeated or lengthy use of general anesthetic and sedation drugs during surgeries or procedures, especially in children younger than 3 years or in fetuses of pregnant women during the third trimester; balance appropriate anesthesia use and timing of elective procedures that can be delayed against potential risks in children younger than 3 years and pregnant women, particularly with procedures that are longer than 3 hours or multiple procedures.
  • Special Populations:
    • Neonate patients are at increased risk of fatal “gasping syndrome” with injection due to benzyl alcohol component, especially with higher doses and in premature or low-birth-weight infants.

ADVERSE EFFECTS

Respiratory depression. Rhythmic myoclonic jerking has occurred in premature neonates receiving LORazepam for sedation.

BLACK BOX WARNING

Risks From Concomitant Use With Opioids. Concomitant use of benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death. Monitor patients for respiratory depression and sedation.

ADMINISTRATION

Intravenous: For intermittent IV use, a concentration of 1 or 2 mg/mL should be infused at a rate not to exceed 2 mg per minute. Avoid intra-arterial administration and perivascular extravasation. In neonates, it might be more practical to use concentrations such as 0.2 mg/mL or 0.4 mg/mL.

MONITORING

Monitor respiratory status closely. Observe IV site for signs of phlebitis or extravasation.

Tags: , , , , ,